Patenting of hot-rolled high-carbon steel and its applications

The patenting process of three hot-rolled steels with carbon mass contents of 0.70%-0. 90% was studied. The effect of the quenching temperature on the cementite lamellar distance in the steel was evaluated on the basis of microstructural characterization and mechanical property tests. The patenting treatment of high-carbon hot- rolled strip and its application in springs were discussed.

The Gender Patenting Gap: A Study on the Iberoamerican Countries

Purpose: This work presents a study on the female involvement in patent applications in all 23 Ibero-American countries that are WIPO members, in order to measure gender inequalities in institutional collaborations and technological fields, across time.Design/methodology/approach: The data used in this paper come from EPO Worldwide Patent Statistical Database(PATSTAT). PATSTAT contains bibliographical data relating to more than 100 million patent documents from leading industrialized and developing countries, as well as legal event data from more than 40 patent authorities contained in the EPO worldwide legal event data(INPADOC). The extracted subset is composed of 150,863 patent applications with priority years between 2007 and 2016.Findings: Our observations indicate that even in more dynamic economies such as Portugal and Spain, the participation of women per patent applications does not exceed 30%. Additionally, the distribution of female participation among institutional sectors and technological fields is consistent with previous studies in other regions and indicate a socio-cultural divide.Research limitations: Unisex names were not considered and were counted as gender unknown, and patent applications for which no inventor information was available were discarded, but further effort of data analysis may provide more information about gender inequalities.Practical implications: While patents are imperfect variables of inventive step and therefore should be considered as a variable proxy of innovation, our findings may help to guide the implementation of policies for balancing gender participation in innovative activities, as well as instigating research into the issues causing divisive participation along gender lines.Originality/value: While there is a widespread effort into evaluating and improving the participation of groups recognized as minorities within state-of-the-art activities, research about women participation in the innovation sector is fragmented due to differing regional characteristics: industrial and academic segmentation, socio-economic disparities, and cultural factors. Thus, localized studies present an opportunity of filling the gaps of knowledge on societal participation in innovation activities.

Chinese Patent, A Tentative Explanation of Various Strategies of Patenting

The recent increase in patent granted in China prompts for an analysis of the various strategies which are certainly developed by Chinese applicants in that field. An analysis （APA Automatic Patent Analysis） has been done in several fields which have different impacts on the Chinese economy. We chose four different subjects： solar panels; photovoltaic panels; fireworks; and honeysuckle. These areas go from deep international concern to only Chinese interest. We analyzed in the different ratios between Chinese priority patents, Chinese patents extended to other countries, Patent extended from other countries to China and Chinese utility models. The results show clearly that various directions are followed depending on the economic importance of the field and also the pressure of the competition inside and outside China. In this context the strategic dependence （number of patents extended to China by other countries） was examined for each of the fields. We also show that in the domain where the man power is important such as fireworks the number of utility models is important. This suggests that utility models are used to spread in that field minor innovations. In the fields such as honeysuckle many applicants are the same that the inventors and the involvement of universities larger than in other fields. These two fields more or less centered on Chinese domestic aspects only a few patents （not for Honeysuckle） are extended to other countries. The impact of foreign patents in these two fields is quasi nil. In other domains such as photovoltaic panel the triadic patents （extension to US JP EP） are examined its show that if some Chinese patents are extended to other countries there are also an important numbers of foreign patents extended to China. This also suggests that in these most critical subjects, China develops a sort of technological protection barrier from domestic patents. This underlines a strategy on attack and defense in that field.

Technological Development on Layered Products for Foods and/or Foodstuff-Evaluation by Patenting Documents

Packaging is one of the most important methods of keeping the quality of food products for storage, transportation and end-use. The price of materials employed for packaging food has traditionally been high and used to be more expensive than the food itself. Technological innovations made possible to produce packaging materials cheaply. One of these processes is known as co-extrusion. This technique makes a film with two or more layers with different plastics not laminating the layers together with an adhesive, eliminating the use of solvents and producing a film in just one step instead multiple steps. In this background, our paper relates to the evolution on packaging for foods by using patenting documents. A search for patent documents was performed on free patent databases using keywords and International Patent Classification （IPC） codes related to this technology. As results： （a） 17% of the 21,472 documents found are focused on multilayer packaging for food; （b） 12 countries hold more than 90% of patents （38% Japan; 23% The United States of America; 7% Canada and 6% Germany）; and, （c） two peaks were perceived in the period of 1992-1994 and 2003, and matches, respectively, the Persian Gulf （1990-1991） and Iraq Wars （2003-invasion of Iraq）, so the historical tendency is confirmed： ＂wars also generate scientific and technological innovations＂.

Patent-based technological developments and surfactants application of lithium-ion batteries fire-extinguishing agent

While newer,more efficient Lithium-ion batteries(LIBs)and extinguishing agents have been developed to reduce the occurrence of thermal runaway accidents,there is still a scarcity of research focused on the application of surfactants in different LIBs extinguishing agents,particularly in terms of patented technologies.The aim of this review paper is to provide an overview of the technological progress of LIBs and LIBs extinguishing agents in terms of patents in Korea,Japan,Europe,the United States,China,etc.The initial part of this review paper is sort out LIBs technology development in different regions.In addition,to compare LIBs extinguishing agent progress and challenges of liquid,solid,combination of multiple,and microencapsulated.The subsequent section of this review focuses on an in-depth analysis dedicated to the efficiency and challenges faced by the surfactants corresponding design principles of LIBs extinguishing agents,such as nonionic and anionic surfactants.A total of 451,760 LIBs-related patent and 20 LIBs-fire-extinguishing agent-related patent were included in the analyses.The extinguishing effect,cooling performance,and anti-recombustion on different agents have been highlighted.After a comprehensive comparison of these agents,this review suggests that temperature-sensitive hydrogel extinguishing agent is ideal for the effective control of LIBs fire.The progress and challenges of surfactants have been extensively examined,focusing on key factors such as surface activity,thermal stability,foaming properties,environmental friendliness,and electrical conductivity.Moreover,it is crucial to emphasize that the selection of a suitable surfactant must align with the extinguishing strategy of the extinguishing agent for optimal firefighting effectiveness.

我国天麻研究态势问题分析及未来发展对策研究——基于20年专利数据为例

天麻(Gastrodia elata Blume)是一种药食同源植物,具有极高的药用和食用价值。专利文献具有创造性、新颖性和实用性,为了解目前我国天麻专利的研究方向及重点,以Patentics数据库为数据源,检索公开日为2003年以来国内天麻专利,利用Excel 2019、Origin 2021工具以及专利计量学,对申请数量、申请地区、申请人、主要发明人、技术领域分布、法律状态和专利地图等方面进行分析。结果发现:近20年天麻专利申请数量呈波浪形变化;不同地区申请数量与地理位置和科技发展水平有关;申请人呈现较强地域性,重点关注领域也有所不同;所属单位相同的发明人存在合作关系;国内天麻专利技术领域分布重点集中于人类生活需要方面;专利地图呈现了天麻专利研究热点以及未来发展方向,具有一定参考意义。研究揭示近20年天麻专利技术分布和研发重点,为天麻未来研究领域和专利布局提供参考和新思路。

Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy:A network meta-analysis

BACKGROUND Iron deficiency anemia(IDA)is a prevalent nutritional disorder during pregnancy.Clinical studies indicate that incorporating Chinese patent medicines(CPMs)with oral iron(OI)in treating IDA in pregnancy can reduce adverse effects and improve clinical outcomes.Nonetheless,the comparative efficacy of different CPMs remains unclear.AIM To assess the safety and effectiveness of different CPMs for treating IDA during pregnancy using network meta-analysis.METHODS We conducted a search for randomized controlled trials(RCTs)that combined CPM and OI for IDA treatment in pregnancy,spanning from 2013 to the present.Data analysis was performed using Rev Man 5.3 and Stata 14.0 on literature that satisfied the quality criteria.RESULTS The analysis included 45 RCTs,encompassing 4422 pregnant patients with IDA.Six CPMs were examined,including Shengxuebao Mixture,Shengxuening Tablets(SXN),Yiqi Weixue CPMs(YQWX),Jianpi Shengxue CPMs(JPSX),Yiqi Buxue Tablets,and Compound Hongyi Buxue Oral Liquid(FFHY).Findings indicated that FFHY+OI significantly improved the clinical effective rate.SXN+OI was most effective in boosting red blood cells counts and hemoglobin levels.YQWX+OI showed superior results in improving serum ferritin,and SXN+OI was most effective in increasing serum iron levels.JPSX+OI was optimal in reducing adverse pregnancy outcomes,while YQBX+OI effectively minimized adverse events.A cluster analysis suggested that SXN+OI could be the potentially optimal therapeutic regimen for IDA in pregnancy.CONCLUSION This study demonstrates that the combination of OI with CPMs offers better outcomes than OI alone.Based on clinical efficacy and other measured outcomes,SXN+OI emerges as the most effective treatment modality for improving the health of pregnant patients with IDA.

Inhibition of hepatitis B virus via selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet

BACKGROUND Liuweiwuling Tablet(LWWL)is a Chinese patent medicine approved for the treatment of chronic inflammation caused by hepatitis B virus(HBV)infection.Previous studies have indicated an anti-HBV effect of LWWL,specifically in terms of antigen inhibition,but the underlying mechanism remains unclear.AIM To investigate the potential mechanism of action of LWWL against HBV.METHODS In vitro experiments utilized three HBV-replicating and three non-HBV-replicating cell lines.The in vivo experiment involved a hydrodynamic injectionmediated mouse model with HBV replication.Transcriptomics and metabolomics were used to investigate the underlying mechanisms of action of LWWL.RESULTS In HepG2.1403F cells,LWWL(0.8 mg/mL)exhibited inhibitory effects on HBV DNA,hepatitis B surface antigen and pregenomic RNA(pgRNA)at rates of 51.36%,24.74%and 50.74%,respectively.The inhibition rates of LWWL(0.8mg/mL)on pgRNA/covalently closed circular DNA in HepG2.1403F,HepG2.2.15 and HepG2.A64 cells were 47.78%,39.51%and 46.74%,respectively.Integration of transcriptomics and metabolomics showed that the anti-HBV effect of LWWL was primarily linked to pathways related to apoptosis(PI3K-AKT,CASP8-CASP3 and P53 pathways).Apoptosis flow analysis revealed that the apoptosis rate in the LWWL-treated group was significantly higher than in the control group(CG)among HBV-replicating cell lines,including HepG2.2.15(2.92%±1.01%vs 6.68%±2.04%,P<0.05),HepG2.A64(4.89%±1.28%vs 8.52%±0.50%,P<0.05)and HepG2.1403F(3.76%±1.40%vs 7.57%±1.35%,P<0.05)(CG vs LWWL-treated group).However,there were no significant differences in apoptosis rates between the non-HBV-replicating HepG2 cells(5.04%±0.74%vs 5.51%±1.57%,P>0.05),L02 cells(5.49%±0.80%vs 5.48%±1.01%,P>0.05)and LX2 cells(6.29%±1.54%vs 6.29%±0.88%,P>0.05).TUNEL staining revealed a significantly higher apoptosis rate in the LWWL-treated group than in the CG in the HBVreplicating mouse model,while no noticeable difference in apoptosis rates between the two groups was observed in the non-HBV-replicating mouse model.CONCLUSION Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV,potentially involving selective regulation of apoptosis.These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.

White Matter Lesions in Young-Middle Aged Migraineurs with Patent Foreman Ovale: A Case-Control Study

Background:White matter lesion(WML)is common in aging brain and is associated with cognitive impairment and dementia.However,recent studies reported an association between patent foramen ovale(PFO)and WML in migraineurs,especially in young,middle-aged migraineurs.Our retrospective,case-control study aims to describe the clinical characteristics of WML in this population and to explore potential risk factors.Methods:226 patients with migraine and PFO were consecutively initially screened.Relevant factors were selected by the least absolute shrinkage and selection operator(LASSO)regression and multivariable logistic regression model.A Nomogram was employed to visualize the prediction model conveniently.The discrimination and calibration abilities were evaluated using the Receiver Operating Characteristic(ROC)curve,the Hosmer-Lemeshow test,and calibration curves.Results:One hundred and nineteen participants were ultimately enrolled in our study,with a median age of 36.9±12.7 years and 80.7%of females.Brain magnetic resonance imaging MRI showed 67(56.3%)patients had WML,whereas 52(43.7%)patients were categorized into the non-WML group.LASSO regression screened out potential variables and subsequent multivariate analysisfinally identified age,mean platelet volume,andfibri-nogen(FIB)as independent predictive factors of WML.The area under the ROC curve(AUC)was 0.807.Hos-mer-Lemeshow test and calibration curve verified a consistency between the predicted and actual probability.Conclusion:The predictive nomogram established and validated in our study may assist clinicians in screening WML among young middle-aged migraineurs with PFO and developing individualized preventive and treatment strategies.

Renewable Biomass as a Platform for Preparing Green Chemistry

1 About the Special Issue Editor Qiaoguang Li is an associate professor and master’s supervisor in the Department of College of Chemistry and Chemical Engineering,Zhongkai University of Agriculture and Engineering.He received his PhD from Institute of Chemical Industry of Forestry Products,Chinese Academy of Forestry in 2018.He has been focusing his research on the chemical basis and application of natural resources.He has published nearly 30 international peer reviewed papers and applied for 10 patents.

Multiple paradoxical embolisms caused by central venous catheter thrombus passing through a patent foramen ovale: A case report

BACKGROUND To date,this is the first case of a paradoxical embolism(PDE)that concurrently manifested in the coronary and lower limb arteries and was secondary to a central venous catheter(CVC)thrombus via a patent foramen ovale(PFO).CASE SUMMARY Here,we report a case of simultaneous coronary and lower limb artery embolism in a PFO patient carrier of a CVC.The patient presented to the hospital with acute chest pain and lower limb fatigue.Doppler ultrasound showed a large thrombus in the right internal jugular vein,precisely at the tip of the CVC.Transthoracic and transesophageal echocardiography confirmed the existence of a PFO,with inducible right-to-left shunting by the Valsalva maneuver.The patient was administered an extended course of anticoagulation therapy,and then the CVC was successfully removed.Percutaneous PFO closure was not undertaken.There was no recurrence during follow-up.CONCLUSION Thus,CVC-associated thrombosis is a potential source for multiple PDE in PFO patients.

Efficacy and safety of Yangxue Qingnao Granules in treatment of migraine:A systematic review and meta-analysis

BACKGROUND Yangxue Qingnao Granules(YXQN)is a Chinese patent medicine that has been commonly used in the clinical treatment of migraine.AIM To assess the efficacy and safety of YXQN alone for the treatment of migraine.METHODS We searched 10 databases to identify relevant randomized controlled trials(RCTs)published before September 2022.Two review authors independently searched and screened the literature,extracted the data,and assessed the methodological quality of the studies using criteria from ROB 2.0,and analyzed the data using Review Manager 5.4 software.RESULTS A total of 12 RCTs including 767 participants with migraine met the selection criteria.We divided these studies into comparisons of YXQN with placebo,routine treatment drugs,and other Chinese patent medicines.The meta-analysis showed the following:(1)Efficacy:The YXQN group outperformed the placebo group[relative risk(RR)=0.29,95%confidence interval(95%CI):0.15–0.43,P<0.00001],routine treatment group(RR=0.18,95%CI:0.09–0.27,P<0.0001),and Chinese patent medicine group(RR=0.27,95%CI:0.13–0.41,P<0.001);(2)frequency of headache:There was a significant difference between YXQN vs placebo[mean difference(MD)=-1.25,95%CI:-1.60 to-0.90,P<0.00001],routine treatment drugs(MD=-0.85,95%CI:-1.15 to-0.56,P<0.00001),and Chinese patent medicine(MD=-0.91,95%CI:-1.35 to-0.46,P<0.0001);(3)headache duration:We found great heterogeneity between studies,with no differences between YXQN and placebo(MD=-0.61,95%CI:-1.53 to-0.31,P=0.19)and routine treatment drugs(MD=-0.22,95%CI:-0.89 to 0.46,P<0.53).YXQN was more effective than other Chinese patent medicines in reducing headache duration(MD=-1.24,95%CI:-1.70 to-0.77,P<0.00001);and(4)headache severity:There was no significant difference between YXQN vs placebo(MD=-1.67,95%CI:-3.52 to 0.19,P=0.08),routine treatment drugs(MD=-0.53,95%CI:-2.02 to 0.96,P=0.68),and other Chinese patent medicines(MD=-0.49,95%CI:-2.83 to 1.85,P=0.68).Mild gastrointestinal adverse reactions were reported in three cases.CONCLUSION This study revealed that YXQN is effective and safe for treatment of migraine.

Simultaneous type III congenital esophageal atresia and patent ductus arteriosus in a low-weight patient: A case report

BACKGROUND We report a low-birth-weight child(1.8 kg)with neonatal type III congenital esophageal atresia(CEA)combined with symptomatic patent ductus arteriosus(PDA).After comprehensive evaluation,esophageal anastomosis was performed on postnatal day 11 after excluding surgical contraindications,and arterial catheter ligation was performed at the same time.Concurrent surgery for CEA combined with PDA has not been clearly reported in the literature.CASE SUMMARY We report a 6-day-old female child with type III CEA and PDA.The patient presented with foam at the mouth after birth,cough and shortness of breath after feeding.At another hospital,she was considered to have neonatal pneumonia,neonatal jaundice and congenital heart disease and transferred to our hospital.After iodine oil radiography of the esophagus and echocardiography we con-firmed diagnosis of CEA and PDA.The diameter of the PDA was 8 mm,with obvious left to right shunting.We performed right rear extrapleural orificium fistula ligation and esophageal anastomosis,and ligation of PDA via left axilla straight incision after 5 d of hospitalization.The operations were successful,and the incision healed after 12 d,and the patient was discharged.We re-examined the patient 1 mo after surgery.She did not vomit when she ate rice flour.Esophageal angiography showed no stricture of the anastomotic stoma.The patient weighed 3.2 kg.CONCLUSION For CEA patients with multiple risk factors,comprehensive,timely and accurate diagnosis and evaluation,and early treatment may improve prognosis.

Idiopathic mesenteric phlebosclerosis missed by a radiologist at initial diagnosis: A case report

BACKGROUND Idiopathic mesenteric phlebosclerosis(IMP)is a rare type of ischemic colitis characterized by thickening of the wall of the right hemicolon and calcification,sclerosis,and fibrosis of mesenteric veins.The diagnosis of IMP is based on typical clinical features and imaging findings.We report a case of IMP that was initially missed by the radiologist.CASE SUMMARY A 77-year-old woman was admitted to the hospital due to chronic diarrhea for over 2 months.She had been consuming Chinese patent medicines(CPM)containing fructus gardeniae for more than 15 years.Colonoscopy revealed an edematous mucosa,bluish-purple discoloration,erosions,and ulcerations throughout the colorectal area.Abdominal computed tomography(CT)showed diffuse mural thickening of the entire colorectum,with tortuous thread-like calcifications in the right hemicolon,left hemicolon,and rectum.Most of the calcifications were located in the mesenteric vein.The diagnosis of IMP was established based on medical history,colonoscopy,CT findings,and histopathological examination.The patient was treated conservatively with papaverine and rifaximin,and CPM was stopped.Her diarrhea symptoms improved,indicating the effectiveness of the treatment.Over the next several years,she took opium alkaloids for an extended period and did not require hospitalization for the aforementioned gastrointestinal disorder.CONCLUSION IMP is a rare gastrointestinal disease affecting Asian populations,possibly related to long-term herbal medicine intake.Accurate imaging analysis is crucial for diagnosis,but insufficient understanding of the disease can lead to misdiagnosis or missed diagnosis.Treatment strategies should be personalized.

Clinical research report on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions(2022)

Objective:The paper is to comprehensively summarize and analyze the basic situation and methodological quality of clinical randomized controlled trials(RCTs)of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions published in 2022,to provide evidence and reasonable suggestions for the advancement of clinical research and the formulation of policies and guidelines.Methods:The Evidence Database System of clinical evidence-based evaluation of traditional Chinese medicine was searched,and data from China National Knowledge Infrastructure(CNKI),PubMed,and other databases were supplemented.The search duration was from January 1,2022,to December 31,2022.RCTs of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were included as the source of clinical evidence,and published information,sample size,intervention,control measures,treatment course,methodological quality,and key link report were analyzed and evaluated.Results:A total of 1,464 RCTs of traditional Chinese patent medicines were included,which comprised 667 types of traditional Chinese patent medicines;“traditional Chinese patent medicines+Western medicine vs.Western medicine”was the most widely used intervention and control setting,involving 417 RCTs(28.48%).A total of 245 RCTs of traditional Chinese classic famous prescriptions were included,comprising 55 types of traditional Chinese classic famous prescriptions.“Decoction+conventional treatment vs.conventional treatment”was the most widely used intervention and control setting,with 87 RCTs(35.51%).Published RCTs on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were limited by the study design and implementation.Most“allocation concealment”and“blinding of patients and personnel”were rated as medium to high risk.There are insufficient reports on key research links such as experimental registration and ethical approval.Conclusions:The number of RCTs on traditional Chinese patent medicines has decreased in 2022,but there has been a slight improvement in the research quality and impact.There are relatively few studies on traditional Chinese classic famous prescriptions.Measures must be taken to improve clinical trial design,implementation,and reporting.Methodological experts should be invited to provide professional technical guidance on the trial design.In the research implementation process,attention should be paid to quality control,particularly the standardization of the randomized execution.

Exploring the Relationship Between Patent Forward Citation and Stock Return Rate Using Empirical Data of China Stock Market

A novel indicator called price-citation was proposed.Based on the company integrated patent database of China listed companies of common stocks(A-shares)with the stock price and the stock return rate data,more than two thousand of A-shares from 2017 to 2020 were selected.The effect of the traditional patent forward citation and the price-citation for discriminating the stock return rate was thoroughly analyzed via ANOVA.The A-shares of forward citation counts above the average showed higher stock return rate means than the A-shares having patents but receiving no forward citations.The price-citation,combining both the financial and patent attributes,defined as the multiplication of the current stock price and the currently receiving forward citation count,showed its excellence in discriminating the stock return rate.The A-shares of higher price-citation showed significantly higher stock return rate means while the A-shares of lower price-citation showed significantly lowest stock return rate means.The price-citation effect had not been changed by COVID-19 though COVID-19 affected the social and economic environment to a considerable extent in 2020.

Intensifying International Beauty Brands' Game against China

The way in which international beauty giants are laying out the Chinese market seems to be quietly changing.I have recently observed that the pace of foreign beauty giants launching self-developed patented ingredients and technologies is accelerating.In particular,a number of relevant achievements have been focused on the November 2023 China International Import Expo.Among them,new patented ingredients/technologies launched in the past year accounted for six cases.They include Shiseido’s Neomyone,Unilever’s Glutathione meta-technology,Amore Pacific's Fonoin,Estee Lauder's Sertiin Age Reversal Technology,Kose’s IPS cell research technology,and Procter&Gamble’s OLAY’s“Collagen Visualization”technology,etc..

CHINA RISES TO WORLD INNOVATION POWERHOUSE

China’s persistent efforts to encourage innovations in science and technology have made remarkable achievements.The Patent Cooperation Treaty(PCT)Yearly Review 2023 gave a detailed report and statistics on global patents over the last year.The PCT is an international patent treaty that provides a unified procedure for filing and processing patent applications and facilitates the seeking of patent protection for inventions in multiple countries.

The Advancements of Medical Textiles:A Patent Perspective

The healthcare sector is advancing in many aspects,including smart devices,surgical robots,AR/VR consultation,etc.Medical textiles are one such aspect where we have observed tremendous growth in innovation.Before the pandemic,the CAGR of patent filing in medical textiles was~12.5%.Postpandemic,it increased to 42.6%.From the patent publishing data,we saw that the US,Japan,India,and Germany are the top four countries in which innovations in medical textiles are on the rise.The extent of the growth is due to the constant improvements and innovations in both textile technology and medical materials.

Analysis of Technical Intelligence of Tumor Cell Therapy Based on Patent Map

Objective To analyze the technical information in the field of tumor cell therapy in China,and to provide reference for identifying technical trends and predicting technical opportunities.Methods Based on the patent data in the field of tumor cell therapy in China,the patent map method was used to construct a scientific technical information analysis model.Then,the technical status of new drug research and development in this field was explored to identify technical opportunities.Results and Conclusion Studies have found that China’s tumor immunotherapy is in the growth stage.The technical innovation regions are mainly distributed in the east and innovative entities are enterprises.Technology hotspots are concentrated in areas such as A61P35,C12N5,and the patented technical efficacy is high.Besides,the technical research and development opportunities identified are closely related to the background in this field.To better promote the development of the industry,enterprises and research institutions should strengthen cooperation in technological innovation Meanwhile,they should pay attention to technical efficacy analysis to identify more technical opportunities,thereby effectively guiding innovation strategic decisions.